

Χαρακτηριστικά:

- Provides the very latest overview of the pathogenesis of systemic lupus erythematosus
- Distills current understanding of the cellular, molecular, genetic, and environmental factors that instigate and drive the disease
- Includes comprehensive coverage of clinical features, including fatigue, organ system manifestations, overlap syndromes, infections, and more
- Conveys the very latest understanding of mechanisms of tissue damage, including immune complexes, antibodies, and other mechanisms that lead to organ damage
- Discusses the latest treatment options on disease modifying or disease controlling agents

Περιεχόμενα:

Part I - Epidemiology and diagnosis

1. Introduction
2. The patient
3. Practicing law with lupus: the story of a patient
4. Epidemiology
5. Measuring disease activity
6. Disease development and outcome
7. Socioeconomic aspects of SLE
8. Biomarkers in systemic lupus erythematosus
9. Biomarkers in lupus nephritis

Part II - Pathogenesis

10. Overview of the pathogenesis of systemic lupus erythematosus
11. System lupus erythematosus and the environment
12. Genes and genetics in human SLE
13. Monogenic lupus
14. Hormones
15. Clinical aspects of the complement system in systemic lupus erythematosus
16. T cells
17. B cells in SLE
18. Neutrophils in systemic lupus erythematosus
19. The role of dendritic cells in systemic lupus erythematosus
20. Platelets in lupus
21. Cytokines
22. RNA/DNA sensing in SLE—Toll-like receptors and beyond
23. The role of interferons in systemic lupus erythematosus
24. Fc γ receptors in autoimmunity and end organ damage
25. Apoptosis, autophagy, and necrosis
26. Infections in early systemic lupus erythematosus pathogenesis

27. Microbiota influences on systemic lupus erythematosus and Sjögren's syndrome
28. Origin of autoantibodies
29. Anti-DNA antibodies
30. Antihistone and antispliceosome antibodies
31. Immune complexes in systemic lupus erythematosus
32. MicroRNA in systemic lupus erythematosus
33. Metabolic control of lupus pathogenesis
34. Epigenetics
35. What do mouse models and genetics teach us about human SLE?

Part III - Mechanisms of tissue damage

36. Mechanisms of renal damage in systemic lupus erythematosus
37. Mechanisms of vascular damage in systemic lupus erythematosus
38. The mechanism of skin damage
39. Pathogenesis of tissue injury in the brain in patients with systemic lupus erythematosus

Part IV - Clinical aspects of the disease

40. Constitutional symptoms and fatigue in systemic lupus erythematosus
41. The musculoskeletal system in SLE
42. Cutaneous lupus erythematosus
43. The clinical evaluation of kidney disease in systemic lupus erythematosus
44. The pathology of lupus nephritis
45. Cardiovascular disease in systemic lupus erythematosus: an update
46. The lung in systemic lupus erythematosus
47. Gastrointestinal, hepatic, and pancreatic disorders in systemic lupus erythematosus
48. Systemic lupus erythematosus and infections
49. Malignancies in systemic lupus erythematosus
50. The nervous system in systemic lupus erythematosus
51. Psychiatric lupus
52. Overlap syndromes
53. Systemic lupus erythematosus and the eye
54. Fertility and pregnancy in systemic lupus erythematosus
55. Neonatal lupus: Clinical spectrum, biomarkers, pathogenesis, and approach to treatment
56. Incomplete lupus syndromes
57. Lupus in children and adolescents
58. Drug-induced lupus
59. Vasculitis in lupus
60. Accrual of organ damage in lupus

Part V - Antiphospholipid Syndrome

61. Pathogenesis of antiphospholipid syndrome
62. Antibodies and diagnostic tests in antiphospholipid syndrome
63. Clinical manifestations

Part VI - Treatment

64. Nonsteroidal anti-inflammatory drugs in systemic lupus erythematosus
65. Value of antimalarial drugs in the treatment of lupus,
66. Systemic glucocorticoids
67. Cytotoxic drug treatment
68. Treatment of antiphospholipid syndrome
69. New treatments of systemic lupus erythematosus
70. Cell therapies in lupus